News from polaris group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 06, 2016, 12:00 ET FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors

 Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20...


Jun 06, 2016, 12:00 ET Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

 Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive...


Jun 03, 2016, 10:00 ET ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining...


Apr 18, 2016, 13:30 ET ADI-PEG 20 is a Potential Salvage Therapy for BRAFi Resistant Melanoma

 Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, is a potential salvage therapy for BRAF...


Nov 11, 2015, 13:30 ET Polaris Group's ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Standard First Line Chemotherapy Regimen

Polaris Group announced today the preliminary results from an ongoing phase 1 study that tests combining its lead therapeutic ADI-PEG 20 (pegylated...


Feb 03, 2015, 13:15 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid...


Jan 20, 2015, 11:13 ET Polaris Transportation Welcomes New Vice President Finance to Their Ranks

MISSISSAUGA, ON, Jan. 20, 2015 /PRNewswire/ - Polaris Transportation Group is pleased to announce the appointment of Jon Saunders as Vice...


Dec 18, 2014, 13:30 ET Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma

 Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation...


Dec 10, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current...


Dec 03, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

 Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with...


Dec 02, 2014, 07:15 ET Polaris Transportation Announces New VP for U.S. Operations

MISSISSAUGA, ON, Dec. 2, 2014 /PRNewswire/ - The management at Polaris Transportation Group is excited to announce the appointment of David Bush as...


Dec 01, 2014, 13:30 ET Data Published by Researchers from Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity through Previously Unidentified Mechanism

 Polaris Group announced today that data from a recent publication in the Proceedings of the National Academy of Sciences of the USA (PNAS)...


Nov 20, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin...


Nov 18, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with doxorubicin for the...


Apr 02, 2014, 17:00 ET Shaw T. Chen, M.D., Ph.D. joins Polaris

 Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as...


Jan 27, 2014, 10:30 ET Polaris Group's ADI-PEG 20 is a Radiosensitizer of Pancreatic Cancer

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic...


Dec 02, 2013, 10:30 ET Polaris Group Files New IND for ADI-PEG 20 in Leukemia

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...


Nov 06, 2013, 15:00 ET Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

 Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated...


Oct 28, 2013, 07:00 ET Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with...


Oct 25, 2013, 17:55 ET Polaris Transport Receives US EPA 2013 SmartWay Excellence Award

TORONTO, Oct. 25, 2013 /PRNewswire/ - Polaris Transport was honored with a SmartWay® Excellence Award from the U.S. Environmental Protection...


Oct 22, 2013, 10:00 ET Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...


Apr 17, 2013, 10:00 ET Metabolic Changes Induced by Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Are Associated with Anticancer Activity in Bladder Cancer and Mesothelioma Models Especially Those That Are Deficient in Key Metabolic Protein

 Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical...


Jun 12, 2012, 09:00 ET Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma

 Scientists from numerous institutions reported at the 2012 annual American Association for Cancer Research meeting, results from preclinical...


Feb 29, 2012, 10:29 ET Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

 Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer...